Patent US4196123A successfully refreshed from Google Patents.
US4196123A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hybrid chorionic gonadotropin preparations and methods for stimulating ovulation using same
Assignee: Individual
•
Filing: 1978-11-20
•
Granted: 1980-04-01
•
Expires: 1998-11-20
Abstract
Abstract A hybrid hormone preparation comprising an admixture of α-chorionic gonadotropin subunits and β-chorionic gonadotropin subunits wherein the ratio of α subunits to β subunits is greater than 1:1, and methods for making and using such preparations, e.g. for stimulating ovulation in female mammals, is described.
Inventors
- 👤 Eugenia Rosemberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 21:45
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/24; C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/59
Claims Analysis
Total Claims: 42
Claim 1
Independent Claim
55 words
A lyophilized hormone preparation comprising a hybridized or recombined product of admixture of α-chorionic gonadotropin subunits and β-chorionic gonadotropin subunits, wherein the ratio of α subunits to β subunits is from about 2:1 to about 8:1, said product being present in an amount sufficient to provide the activity equivalent to at least 1 IU hCG-IS.
Claim 2
Dependent Claim
55 words
A lyophilized hormone preparation comprising a hybridized or recombined product of admixture of α-chorionic gonadotropin subunits and β-chorionic gonadotropin subunits, wherein the ratio of α subunits to β subunits is from about 2:1 to about 8:1, said product being present in an amount sufficient to provide the activity equivalent to at least 1 IU hCG-IS.
Claim 3
Dependent Claim
11 words
A lyophilized hybrid hormone composition comprising the preparation of claim 1.
Claim 4
Dependent Claim
18 words
The hormone preparation of claim 1 wherein the ratio of α subunits to β subunits is about 3:1.
Claim 5
Dependent Claim
22 words
The hormone preparation of claim 1 wherein the ratio of α subunits to β subunits is from about 2.5:1 to about 5:1.
Claim 6
Dependent Claim
28 words
The hormone preparation of claim 1 wherein each of said α subunits and said β subunits contain less than 5 wt percent native chorionic gonadotropin as an impurity.
Claim 7
Dependent Claim
11 words
A frozen hybrid hormone composition comprising the preparation of claim 1.
Claim 8
Dependent Claim
20 words
The hormone preparation of claim 1, wherein the α-chorionic gonadotropin subunits and β-chorionic gonadotropin subunits are human chorionic gonadotropin subunits.
Claim 9
Dependent Claim
11 words
A lyophilized hybrid hormone composition comprising the preparation of claim 7.
Claim 10
Dependent Claim
18 words
The hormone preparation of claim 7 wherein the ratio of α subunits to β subunits is about 3:1.
Claim 11
Dependent Claim
22 words
The hormone preparation of claim 7 wherein the ratio of α subunits to β subunits is from about 2.5:1 to about 5:1.
Claim 12
Dependent Claim
28 words
The hormone preparation of claim 7 wherein each of said α subunits and said β subunits contain less than 5 wt percent native chorionic gonadotropin as an impurity.
Claim 13
Dependent Claim
11 words
A frozen hybrid hormone preparation having the composition of claim 7.
Claim 14
Dependent Claim
32 words
An ampoule of a hybrid hormone preparation as claimed in any one of claims 1, 3, 4, 5, 7, 9, 10, or 11 having an activity equivalent to about 10,000 IU hCG-IS.
Claim 15
Dependent Claim
32 words
An ampoule of a hybrid hormone preparation as claimed in any one of claims 1, 3, 4, 5, 7, 9, 10 or 11 having an activity equivalent to about 5,000 IU hCG-IS.
Claim 16
Dependent Claim
55 words
A frozen hormone preparation having chorionic gonadotropin activity prepared by hybridizing α-chorionic gonadotropin subunits and β-chorionic gonadotropin subunits, the ratio of α subunits to β subunits being from about 2:1 to about 8:1, in amounts such that the hybridized product provides the activity equivalent to at least 1 IU hCG-IS, and freezing the hybridized product.
Claim 17
Dependent Claim
55 words
A frozen hormone preparation having chorionic gonadotropin activity prepared by hybridizing α-chorionic gonadotropin subunits and β-chorionic gonadotropin subunits, the ratio of α subunits to β subunits being from about 2:1 to about 8:1, in amounts such that the hybridized product provides the activity equivalent to at least 1 IU hCG-IS, and freezing the hybridized product.
Claim 18
Dependent Claim
9 words
A lyophilized composition comprising the preparation of claim 15.
Claim 19
Dependent Claim
18 words
The hormone preparation of claim 15 wherein the ratio of α subunits to β subunits is about 3:1.
Claim 20
Dependent Claim
22 words
The hormone preparation of claim 15 wherein the ratio of α subunits to β subunits is from about 2.5:1 to about 5:1.
Claim 21
Dependent Claim
28 words
The hormone preparation of claim 15 wherein each of said α subunits and said β subunits contain less than 5 wt percent native chroionic gonadotropin as an impurity.
Claim 22
Dependent Claim
11 words
A frozen hybrid hormone preparation having the composition of claim 15.
Claim 23
Dependent Claim
29 words
A hormone preparation in accord with any one of claims 15, 17, 18 or 19 wherein said α-chorionic gonadotropin subunit and said β-chorionic gonadotropin subunits is of human origin.
Claim 24
Independent Claim
62 words
A method for stimulating ovulation in mammals comprising administering a hormone preparation comprising a hybridized or recombined product of admixture of α-chorionic gonadotropin subunits and β-chorionic gonadotropin subunits wherein the ratio of α subunits to β subunits is from about 2:1 to about 8:1, said preparation having chroionic gonadotropin hormone activity equivalent to at least 1 international unit of international standard hCG.
Claim 25
Independent Claim
62 words
A method for stimulating ovulation in mammals comprising administering a hormone preparation comprising a hybridized or recombined product of admixture of α-chorionic gonadotropin subunits and β-chorionic gonadotropin subunits wherein the ratio of α subunits to β subunits is from about 2:1 to about 8:1, said preparation having chroionic gonadotropin hormone activity equivalent to at least 1 international unit of international standard hCG.
Claim 26
Dependent Claim
23 words
The method of claim 22 wherein the ratio of α subunits to β subunits is greater than 1:1 and less than about 5:1.
Claim 27
Dependent Claim
17 words
The method of claim 22 wherein the ratio of α subunits to β subunits is about 3:1.
Claim 28
Dependent Claim
27 words
The method of claim 22 wherein each of said α subunits and said β subunits contain less than 5 wt percent native chorionic gonadotropin as an impurity.
Claim 29
Independent Claim
25 words
The method of any one of claims 22, 24 or 25 wherein said α-chorionic gonadotropin subunit and said β-chorionic gonadotropin subunit is of human origin.
Claim 30
Independent Claim
24 words
The method of any one of claims 22 or 24 through 26 wherein said hormone preparation contains an activity equivalent to 10,000 IU hCG-IS.
Claim 31
Independent Claim
24 words
The method of any one of claims 22 or 24 through 26 wherein said hormone preparation contains an activity equivalent to 5,000 IU hCG-IS.
Claim 32
Dependent Claim
62 words
A pharmaceutical preparation comprising a hybridized or recombined product of admixture of α-chorionic gonadotropin subunits and β-chorionic gonadotropin subunits, the ratio of α subunits to β subunits being from about 2:1 to about 8:1, said product being present in an amount sufficient to provide the activity equivalent to at least 1 IU hCG-IS, and said product being in a pharmaceutically acceptable carrier.
Claim 33
Dependent Claim
62 words
A pharmaceutical preparation comprising a hybridized or recombined product of admixture of α-chorionic gonadotropin subunits and β-chorionic gonadotropin subunits, the ratio of α subunits to β subunits being from about 2:1 to about 8:1, said product being present in an amount sufficient to provide the activity equivalent to at least 1 IU hCG-IS, and said product being in a pharmaceutically acceptable carrier.
Claim 34
Dependent Claim
17 words
The preparation of claim 29 wherein the ratio of α subunits to β subunits is about 3:1.
Claim 35
Dependent Claim
21 words
The preparation of claim 29 wherein the ratio of α subunits to β subunits is from about 2.5:1 to about 5:1.
Claim 36
Dependent Claim
27 words
The preparation of claim 29 wherein each of said α subunits and said β subunits contains less than 5 wt percent native chorionic gonadotropin as an impurity.
Claim 37
Dependent Claim
18 words
The preparation of claim 29 wherein said α and β subunits are α and β human gonadotropin subunits.
Claim 38
Independent Claim
29 words
A method for stimulating ovulation in mammals comprising administering by injection the preparation of any of claims 29 or 30 wherein said pharmaceutically acceptable carrier is a liquid carrier.
Claim 39
Independent Claim
67 words
A method of reducing the risks of multiple gestation in treating anovulatory infertility in female mammals, comprising administering a chorionic gonadotropin agent in an amount which is effective to stimulate ovulation, said chorionic gonadotropin agent comprising a hybridized or recombined product of admixture of α-chorionic gonadotropin subunits and β-chorionic gonadotropin subunits having a ratio of α subunits to β subunits of between about 2:1 and about 8:1.
Claim 40
Independent Claim
67 words
A method of reducing the risks of multiple gestation in treating anovulatory infertility in female mammals, comprising administering a chorionic gonadotropin agent in an amount which is effective to stimulate ovulation, said chorionic gonadotropin agent comprising a hybridized or recombined product of admixture of α-chorionic gonadotropin subunits and β-chorionic gonadotropin subunits having a ratio of α subunits to β subunits of between about 2:1 and about 8:1.
Claim 41
Dependent Claim
24 words
The method of claim 35, further comprising administering effective amounts of luteinizing hormone and follicle stimulating hormone, prior to administering said chorionic gonadotropin agent.
Claim 42
Dependent Claim
17 words
The preparation of claim 29, 30, 31, 32 or 33 wherein the pharmaceutrically acceptable carrier comprises lactose.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-04-01 | 1983-10-01 | 1984-04-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-04-01 | 1987-10-01 | 1988-04-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-04-01 | 1991-10-01 | 1992-04-01 | $7700.00 | Window Closed / Lapsed |